No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
WST240816P290000
- 6.02
- +2.22+58.42%
15min DelayClose Jul 19 15:59 ET
6.02High5.23Low
5.23Open3.80Pre Close1.09K Volume1.26K Open Interest290.00Strike Price569.83KTurnover53.27%IV10.68%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry6.02Extrinsic Value100Contract SizeAmericanOptions Type-0.2290Delta0.0067Gamma49.29Leverage Ratio-0.2547Theta-0.0509Rho-11.29Eff Leverage0.2568Vega
Intraday
- 5D
- Daily
News
A Look At The Fair Value Of West Pharmaceutical Services, Inc. (NYSE:WST)
Key Insights Using the 2 Stage Free Cash Flow to Equity, West Pharmaceutical Services fair value estimate is US$320 With US$327 share price, West Pharmaceutical Services appears to be trading
Does West Pharmaceutical Services (WST) Have Attractive Growth Drivers?
Stephens Adjusts Price Target on West Pharmaceutical Services to $400 From $420
West Pharmaceutical Services (WST) has an average outperform rating and a price target range of $336 to $470, according to analysts polled by Capital IQ.Price: 319.00, Change: -1.11, Percent Change: -
Is It Time To Consider Buying West Pharmaceutical Services, Inc. (NYSE:WST)?
West to Host Second-Quarter 2024 Conference Call
West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it...
What to Expect From West Pharmaceutical Services' Q2 2024 Earnings Report
Comments
RECAP
U.S. equity indexes rose after Thursday, with the $Nasdaq Composite Index(.IXIC.US$ lagging the pack, as investors weighed retail sales and jobless claims ahead of more inflation data this week.
The $S&P 500 Index(.SPX.US$ rose 0.58% to 5,029, a new closing high with the $Dow Jones Industrial Average(.DJI.US$ up 0.91% to 38,664. The $Nasdaq Composite Index(.IXIC.US$ was moderately higher at 15,906, af...
U.S. equity indexes rose after Thursday, with the $Nasdaq Composite Index(.IXIC.US$ lagging the pack, as investors weighed retail sales and jobless claims ahead of more inflation data this week.
The $S&P 500 Index(.SPX.US$ rose 0.58% to 5,029, a new closing high with the $Dow Jones Industrial Average(.DJI.US$ up 0.91% to 38,664. The $Nasdaq Composite Index(.IXIC.US$ was moderately higher at 15,906, af...
41
5
Analysts worry about the company's shifting tone and the enduring effect of clients' inventory management on West's finances. Doubts also arise about the company's demand visibility and if current trends suggest a fundamental issue in West's base business.
Jefferies analyst David Windley sees FDA approvals of GLP-1s for obesity treatment as a huge opportunity for the manufacturing supply chain. He also notes high rivalry in the injectable fill/finish market. Windley upgraded West Pharmaceutical to Buy, raising its price target by 66% to $536, citing its global footprint and capacity to meet growing GLP-1s demand.
The market sentiment around West Pharmaceutical Services hasn't changed much over the past five years, with the share price seemingly reacting to the EPS. The recent improvement in TSR could indicate that the business is getting better with time.
1
Read more